Key facts
- Spinnaker Biosciences’s last known valuation is $4.5M (Dec 2024).
- It has raised $2.6M across 2 recorded rounds; the latest was Seed Round ($667K) in Nov 2024.
- Notable investors include U.S. Department of Health and Human Services.
- Spinnaker Biosciences has filed 3 Form Ds with the SEC since 2010, most recently Dec 2024 ($667K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Spinnaker Biosciences
Funding rounds
2 roundsAbout Spinnaker Biosciences
Developer of nano porous silicon particles intended for controlled-release drug delivery. The company's process allows the manufacture of nano-pores precisely tuned to accommodate the dimensions of a drug of interest and provides a protective cage for the drug and yields control over the rate of release of the drug and the dissolution of the particles, enabling healthcare professionals to develop composite materials to make controlled release drug delivery vehicles.
- Sector
- Healthcare
- HQ
- Solana Beach, CA, United States
- Founded
- 2009
- Employees
- 3
- Website
- spinnakerbiosciences.com/
- Ownership
- Privately Held (backing)
Spinnaker Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Spinnaker Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Spinnaker Biosciences in its N-PORT filings yet. We sweep new filings monthly.